A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Locally Advanced Solid Tumors Metastatic Solid Tumors Lymphoma Primary CNS Tumors ALK ROS1 NTRK1-3 Primary CNS tumor anaplastic large cell lymphoma metastatic solid tumor advanced solid tumor sarcoma infantile fibrosarcoma glioblastoma soft tissue schwannoma solitary fibrous tumor glioma inflammatory myofibroblastic tumor pediatric Neoplasms Central Nervous System Neoplasms Oral repotrectinib (TPX-0005) Repotrectinib (TPX-0005)
Lead Scientist at University of California Health
- Noah Federman, MD (ucla)
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers.
- accepting new patients
- Start Date
- Completion Date
- Turning Point Therapeutics, Inc.
- Phase 1/2 research study
- Study Type
- Expecting 75 study participants
- Last Updated